Advanced search
1 file | 405.54 KB Add to list

Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1 : a Phase IIa randomised controlled study

Author
Organization

Downloads

  • Safety tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464 an investigational antiviral drug in individuals living with HIV-1 a Phase IIa randomised controlled study.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 405.54 KB

Citation

Please use this url to cite or link to this publication:

MLA
Rutsaert, Sofie et al. “Safety, Tolerability and Impact on Viral Reservoirs of the Addition to Antiretroviral Therapy of ABX464, an Investigational Antiviral Drug, in Individuals Living with HIV-1 : a Phase IIa Randomised Controlled Study.” JOURNAL OF VIRUS ERADICATION 5.1 (2019): 10–22. Print.
APA
Rutsaert, Sofie, Steens, J.-M., Gineste, P., Cole, B., Kint, S., Barrett, P. N., Tazi, J., et al. (2019). Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1 : a Phase IIa randomised controlled study. JOURNAL OF VIRUS ERADICATION, 5(1), 10–22.
Chicago author-date
Rutsaert, Sofie, Jean-Marc Steens, Paul Gineste, Basiel Cole, Sam Kint, P Noel Barrett, Jamal Tazi, Didier Scherrer, Hartmut J Ehrlich, and Linos Vandekerckhove. 2019. “Safety, Tolerability and Impact on Viral Reservoirs of the Addition to Antiretroviral Therapy of ABX464, an Investigational Antiviral Drug, in Individuals Living with HIV-1 : a Phase IIa Randomised Controlled Study.” Journal of Virus Eradication 5 (1): 10–22.
Chicago author-date (all authors)
Rutsaert, Sofie, Jean-Marc Steens, Paul Gineste, Basiel Cole, Sam Kint, P Noel Barrett, Jamal Tazi, Didier Scherrer, Hartmut J Ehrlich, and Linos Vandekerckhove. 2019. “Safety, Tolerability and Impact on Viral Reservoirs of the Addition to Antiretroviral Therapy of ABX464, an Investigational Antiviral Drug, in Individuals Living with HIV-1 : a Phase IIa Randomised Controlled Study.” Journal of Virus Eradication 5 (1): 10–22.
Vancouver
1.
Rutsaert S, Steens J-M, Gineste P, Cole B, Kint S, Barrett PN, et al. Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1 : a Phase IIa randomised controlled study. JOURNAL OF VIRUS ERADICATION. 2019;5(1):10–22.
IEEE
[1]
S. Rutsaert et al., “Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1 : a Phase IIa randomised controlled study,” JOURNAL OF VIRUS ERADICATION, vol. 5, no. 1, pp. 10–22, 2019.
@article{8610579,
  author       = {Rutsaert, Sofie and Steens, Jean-Marc and Gineste, Paul and Cole, Basiel and Kint, Sam and Barrett, P Noel and Tazi, Jamal and Scherrer, Didier and Ehrlich, Hartmut J and Vandekerckhove, Linos},
  issn         = {2055-6640},
  journal      = {JOURNAL OF VIRUS ERADICATION},
  language     = {eng},
  number       = {1},
  pages        = {10--22},
  title        = {Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1 : a Phase IIa randomised controlled study},
  volume       = {5},
  year         = {2019},
}